Last $2.51 USD
Change Today +0.01 / 0.40%
Volume 111.9K
NEPT On Other Exchanges
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

neptune tech & bioressources (NEPT) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/29/13 - $4.24
52 Week Low
04/7/14 - $2.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

neptune tech & bioressources (NEPT) Related Businessweek News

No Related Businessweek News Found

neptune tech & bioressources (NEPT) Details

Neptune Technologies & Bioressources Inc., a biotechnology company, focuses on the research, development, and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries. It produces marine-derived omega-3 polyunsaturated fatty acids, including Neptune Krill Oil (NKO), a dietary supplement for heart, joint, women, and brain health; ECOKRILL Oil (EKO), a krill product; and Neptune Krill Aquatein (NKA), a protein ingredient used in the production of nursing feed for young animals. The company is also developing CaPre, which is in Phase II clinical trials for the management of mild to moderate hypertriglyceridemia and severe hypertriglyceridemia, as well as develops and commercializes pharmaceutical applications for cardiovascular and neurological diseases. Neptune Technologies & Bioressources sells its products in Canada, the United States, France, Belgium, Australia, and other countries. The company was founded in 1925 and is headquartered in Laval, Canada.

117 Employees
Last Reported Date: 05/22/14
Founded in 1925

neptune tech & bioressources (NEPT) Top Compensated Officers

Interim Chief Executive Officer, Interim Pres...
Total Annual Compensation: C$164.1K
Chief Global Strategic Officer
Total Annual Compensation: C$196.0K
Chief Financial Officer of Acasti Pharma
Total Annual Compensation: C$23.1K
Chief Operating Officer of Acasti
Total Annual Compensation: C$19.9K
Senior Vice-President of Global Sales
Total Annual Compensation: C$175.2K
Compensation as of Fiscal Year 2014.

neptune tech & bioressources (NEPT) Key Developments

Neptune Technologies & Bioressources, Inc. Announces Changes to Board of Directors

Neptune Technologies & Bioressources, Inc. that at its Annual and Special Meeting held on June 19, 2014, the corporation's shareholders elected Mr. Pierre Fitzgibbon, Mr. Adrian Montgomery, Mr. John Moretz and Mr. Jerald J. Wenker as four new directors. Mr. Henri Harland and Mr. Daniel Perry did not stand for re-election to the Board. Mr. Perry resigned from the Board on June 18, 2014.

Neptune Technologies & Bioressources Inc. Receives All Required Operating Permits for its Sherbrooke, Quebec, Canada Production Facility

Neptune Technologies & Bioressources Inc. announced that its Sherbrooke, Quebec, Canada production facility has received all required operating permits and production will now commence. Production will commence gradually and the corporation anticipates a ramp up period of around 90 days before reaching production capacity of approximately 150 metric tons of krill oil annually. The plant will focus on producing Neptune's premium krill oil, NKO, the original krill oil, with the high concentration of omega-3 phospholipids in the industry and strong brand awareness. Later 2014, Neptune will also make available three new condition-specific formulations, including: NKO BEAT: supports heart health and blood circulation - NKO FLEX: supports bone and joint health - NKO FOCUS: supports brain and vision health. Each of the new formulations have NKO® as the main component along with additional ingredients to support the specific areas of the body targeted, such as Coenzyme Q10 (CoQ10) for the heart, vitamin D for bone and joint health; and thiamine and lutein for the brain and vision.

Henri Harland Files Lawsuit against Neptune and its Subsidiaries

Neptune Technologies & Bioressources Inc., Acasti Pharma Inc. and NeuroBioPharm Inc. jointly announce that Henri Harland, the former President and Chief Executive Officer of each of Neptune, Acasti and NeuroBio, has filed a lawsuit against Neptune and its subsidiaries in connection with his departure as President and Chief Executive Officer of each of Neptune, Acasti and NeuroBio. Mr. Harland resigned as President and Chief Executive Officer of Neptune, Acasti and NeuroBio on April 28, 2014. Among other things, Mr. Harland is alleging that his resignation occurred as a result of a constructive dismissal and is seeking approximately $8.5 million in damages, interest and costs. In addition, Mr. Harland is seeking from Neptune, Acasti and NeuroBio, as applicable, the issuance of 500,000 shares of each of Neptune, Acasti and NeuroBio as well as two blocks of 1,000,000 call options each on the shares held by Neptune in Acasti and NeuroBio. As a result of these circumstances, Mr. Harland has been requested to resign as Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEPT:US $2.51 USD +0.01

NEPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Badger Meter Inc $50.72 USD -0.47
Enzymotec Ltd $14.93 USD -0.10
Itron Inc $40.77 USD -0.31
Targeted Medical Pharma Inc $0.80 USD -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation NEPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.9x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEPTUNE TECH & BIORESSOURCES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at